Condition
Diabetes Mellitus, Type 1
Locations
Japan
Start date
15/04/2025
Identifiers
Trial ID
NN1436-7680,
NCT number NCT06807190,
Eudract number Not Available
NCT number NCT06807190,
Eudract number Not Available
Summary
The purpose of the study is to investigate the safety and effectiveness of Awiqli in participants with diabetes mellitus under real world clinical practice in Japan. Participants will get Awiqli as prescribed by the study doctor. The study will last for about 1 year.
Trial Overview:
Treatment
DRUG: Insulin Icodec
Study type
OBSERVATIONAL
Trial duration
Apr 15 2025 - Jan 31 2028
Participants
630
Phase
Not Available
Are you eligible?
Gender
Male and female
Age
Not Available
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.